BiotechTube
Home/Aurion Biotech/Shigeru Kinoshita, MD, PhD
SK

Shigeru Kinoshita, MD, PhD

Medical Advisor

Aurion Biotech

Therapeutic Areas

OphthalmologyRegenerative Medicine

Aurion Biotech Pipeline

DrugIndicationPhase
VyznovaBullous Keratopathy (Corneal Endothelial Disease)Approved/Commercial
AURN001 (neltependocel + Y-27632)Corneal Endothelial DiseasePhase 3
Cryopreserved AURN001Corneal Endothelial DiseaseClinical Stage

Leadership Team at Aurion Biotech

AL
Arnaud Lacoste, PhD, MBA
Co-founder, Chief Executive Officer and Chief Scientific Officer
EP
Eris P. Jordan, OD
Co-founder and Chief Development Officer
EJ
Edward J. Holland, MD
Chief Medical Officer
AT
Andrew Torres, PhD
Chief Manufacturing Officer
SC
Sterling Chung
Chief Regulatory & Quality Officer
BS
Brad Shutzberg
Vice President, Finance & Infrastructure
SR
Sara Rosetti, PhD
Vice President, Human Resources
JO
J.D. Osborne, MBA
Vice President, Alliance Management
JW
Jen Watts, M.S.
Vice President, Global Head of Clinical Operations
HC
Heidi Chandler
Executive Director, Head of Program Management
View full Aurion Biotech profile